Asset Details
Do you wish to reserve the book?
Treatment of Diarrhea Caused by Giardia intestinalis and Entamoeba histolytica or E. dispar: A Randomized, Double‐Blind, Placebo‐Controlled Study of Nitazoxanide
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Treatment of Diarrhea Caused by Giardia intestinalis and Entamoeba histolytica or E. dispar: A Randomized, Double‐Blind, Placebo‐Controlled Study of Nitazoxanide
Do you wish to request the book?
Treatment of Diarrhea Caused by Giardia intestinalis and Entamoeba histolytica or E. dispar: A Randomized, Double‐Blind, Placebo‐Controlled Study of Nitazoxanide
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Treatment of Diarrhea Caused by Giardia intestinalis and Entamoeba histolytica or E. dispar: A Randomized, Double‐Blind, Placebo‐Controlled Study of Nitazoxanide
2001
Overview
A prospective randomized, double‐blind, placebo‐controlled study was conducted to assess the efficacy and safety of nitazoxanide in the treatment of diarrhea caused by Giardia intestinalis or Entamoeba histolytica and/or E. dispar in 89 adults and adolescents, 22 of whom were diagnosed with G. intestinalis, 53 with E. histolytica and/or E. dispar, and 14 with both G. intestinalis and E. histolytica and/or E. dispar. The study medication was administered as 1 nitazoxanide 500‐mg tablet or a matching placebo twice daily for 3 days. Thirty‐eight (81%) of 47 patients in the nitazoxanide treatment group resolved diarrhea within 7 days (median, 3 days) after initiation of treatment, versus 17 (40%) of 42 in the placebo group (P=.0002). With its efficacy in treating a broad spectrum of enteric protozoan pathogens, nitazoxanide could play an important role in the management of diarrhea caused by enteric protozoa, reducing morbidity and costs associated with these diarrheal illnesses.
Publisher
University of Chicago Press,Oxford University Press
Subject
/ Adult
/ Aged
/ Animals
/ Antibiotics. Antiinfectious agents. Antiparasitic agents
/ Antiprotozoal Agents - therapeutic use
/ Biological and medical sciences
/ Child
/ Diarrhea
/ Dysentery, Amebic - complications
/ Dysentery, Amebic - drug therapy
/ Entamoeba - isolation & purification
/ Entamoeba histolytica - isolation & purification
/ Entamoebiasis - complications
/ Entamoebiasis - drug therapy
/ Female
/ Giardia lamblia - isolation & purification
/ Humans
/ Male
/ Pharmacology. Drug treatments
/ Placebos
